Opendata, web and dolomites

CXCR4THERAPY TERMINATED

IMPROVING HEMATOPOIETIC STEM CELL- BASED GENE THERAPY OUTCOME BY MODULATING CXCR4 EXPRESSION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CXCR4THERAPY project word cloud

Explore the words cloud of the CXCR4THERAPY project. It provides you a very rough idea of what is the project "CXCR4THERAPY" about.

advantage    lentiviral    hurdle    mediated    receptor    reduce    severely    competition    data    normally    chemokine    despite    abnormal    sickle    vector    migration    strategies    transplantation    lvs    hemoglobin    restricted    introduction    alternative    explored    caused    burden    transiently    followed    homed    hscs    clinical    globin    variant    attaining    fact    correction    compete    option    potentially    milder    endow    thanks    functional    lv    synthesis    amenable    copy    confer    patients    therapy    compatible    repopulating    therapeutic    proliferation    hematopoietic    capacity    defective    competitive    modulating    cells    haploinsufficiency    disease    stem    homing    bone    transduced    intend    curative    conditioning    allogeneic    limited    donors    marrow    strategy    cell    treatment    inefficient    gene    bm    beta    levels    toxicity    endogenous    diseases    vivo    regulating    innovative    broad    eliminate    preclude    mutations    corrected    enhances    scd    engraftment    hbb    benefit    expression    regimen    autologous    efficiencies    thalassemias    cxcr4    hsc    noteworthy   

Project "CXCR4THERAPY" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 173˙076 €
 EC max contribution 173˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 173˙076.00

Map

 Project objective

β-thalassemias and sickle cell disease (SCD) are caused by mutations in the β-globin gene (HBB) that result in the defective synthesis (β-thalassemias) or the production of an abnormal variant (SCD) of hemoglobin. Currently, the only curative option is allogeneic transplantation of hematopoietic stem cells (HSCs), but it is severely limited by conditioning toxicity and the restricted availability of compatible donors. Alternative strategies, based on lentiviral vector (LV)-mediated introduction of a functional copy of the HBB gene followed by autologous transplantation, are currently explored. Despite the fact that clinical data are promising, achieving a broad therapeutic benefit still remains a major hurdle because of inefficient gene correction and competition of the endogenous affected HSCs. In this proposal, I intend to confer an in vivo competitive advantage to transduced HSCs in terms of homing and engraftment efficiencies by modulating the expression levels of the chemokine receptor CXCR4 through two different approaches. On one hand, as increased CXCR4 levels enhance bone marrow (BM) homing, I will develop an innovative LV-based strategy to transiently deliver CXCR4 into HSCs to improve their migration to the BM. On the other hand, as CXCR4 haploinsufficiency enhances proliferation of homed HSCs, I will develop LVs down-regulating CXCR4 expression to endow corrected HSCs with an increased BM repopulating capacity. Thanks to these strategies, corrected HSCs will be able to out-compete non-corrected as well as endogenous affected HSCs, thus attaining therapeutic levels of engraftment even with a reduced number of corrected HSCs. In addition, this will contribute to use a milder conditioning regimen, normally required to eliminate endogenous affected HSCs, and thus reduce its toxicity, which preclude this treatment for patients with high disease burden. Noteworthy, this approach can potentially benefit many diseases amenable to HSC gene therapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CXCR4THERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CXCR4THERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  

STUDYES (2019)

Structure and Ultrafast Dynamics in Deep Eutectic Solvents

Read More  

Cartesian Networks (2020)

Cartesian Networks in Early Modern Europe: A Quantitative and Interdisciplinary Approach

Read More